Zhejiang Kanglaite Pharmaceutical Co., Ltd., established by Prof. Li Dapeng, is a “State Key High-tech Enterprise” . Covering an area of 7 hectares and a total floor space of 28,000 sq. m, the LVP production line and auxiliary equipment were introduced from Europe and USA. International GMP standard is strictly followed in production. There are over 500 staff of whom 60% are with university diploma. We have 32 regional offices in China.

As “ State Basic Drug” and “State Medical Insurance Drug”, the company mainly produces botanical anticancer drug Kanglaite Injection (KLT) which is a novel dual-function and molecular targeted emulsion with active substance extracted from a TCM herb “semen coicis” . KLT has remarkable function in inhibiting and killing cancer cells while strengthening immune function. It has significant effectiveness in controlling cancerous pain, resisting cachexia, preventing cancer metastasis and recurrence, improving KPS, QOL and MST and effectively prolonging patient survival.

KLT has full intellectual property. Its chemical component, process technology and application have obtained patent certificates from over 10 countries in the world. In 2001 FDA approved KLT to start clinical study in USA and the Russian Ministry of Health issued KLT registration certificate in December 2003. New pharmaceuticals like “Gingko Leave Soft Capsule”, “Co-Enzyme Q10” and fat emulsion have been added to the product catalogue in recent years.

We are seeking overseas agent to distribute KLT with preferential policy.